Get started
Author

Kotoe Matsuda

ORCID: 0009-0004-6941-0750
Observed ORCID: 0009-0004-6941-0750
OpenAlex ID: A5113280511
Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al. · Cancer Research Communications · 1
PDF
[Two Cases of Bleeding from the Ileal Conduit Due to Ectopic Varices].
2024 · Takuto Yamasaki, Takayuki Yoshino, et al. · PubMed · 1
PDF
Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First‐Line, Immune‐Based Combinations
2026 · Hiromichi Sakurai, Masanobu Shiga, et al. · Cancer Reports
Table 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Supplemental Table 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Data from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Table 4 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Figure 2 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Figure 3 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Table 3 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Table 2 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Limited Response to Enfortumab Vedotin‐Pembrolizumab in Three Consecutive Cases of Neoadjuvant Chemotherapy‐Resistant Muscle‐Invasive Bladder Cancer
2025 · Kotoe Matsuda, Masakazu Tsutsumi, et al. · International Journal of Urology
Works count: 13
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type